Rosiglitazone and cardiovascular risk. The New England journal of medicine [N Engl J Med] Journal article

Title	Rosiglitazone and cardiovascular risk.
Author(s)	Psaty BM, Furberg CD
Source	N Engl J Med 2007 Jun 14; 356(24):2522-4.
MeSH	Adverse Drug Reaction Reporting Systems Cardiovascular Diseases Clinical Trials, Phase IV Diabetes Mellitus, Type 2 Drug Approval Humans Hypoglycemic Agents Meta-Analysis Myocardial Infarction Randomized Controlled Trials Risk Assessment Thiazolidinediones United States United States Food and Drug Administration
Language	eng
Pub Type(s)	Comment Editorial
PubMed ID	17517854

Advertise on this site.